ESZOPICLONE

Post-LOE

eszopiclone

Aurobindo Pharma

ANDAORALTABLET1 Generic Approved

Approved

Sep 2016

Lifecycle

Post-LOE

Competitive Pressure

45/100

Clinical Trials

Data completeness

3/8 — Basic

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (9)

NCT06452953N/ACompleted

Modified Suanzaoren Decoction Versus Eszopiclone for the Treatment of Chronic Insomnia Disorder

Started Sep 2020

85 enrolled

Chronic Insomnia Disorder

NCT02452684N/ACompleted

Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients

Started Oct 2012

4,876 enrolled

Insomnia

NCT02455271N/ACompleted

Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients

Started Oct 2012

438 enrolled

Insomnia

NCT00770692Phase 3Completed

A Phase III Study of Eszopiclone in Patients With Insomnia (Study SEP 190-150)

Started Oct 2008

369 enrolled

Insomnia

NCT00770510Phase 2/3Completed

A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)

Started Sep 2008

192 enrolled

Primary Insomnia

Worked on ESZOPICLONE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.